IFNγ treatment block M-MDSC to produce the tumor-promoting molecule nitric oxide (NO) and PGE2, which promote nuclear accumulation of P50 NF-κB in M-MDSCs, indicating that IFNγ treatment may reverse NO-mediated immunosuppression of MDSCs through PGE2/NO/P50 pathways (53). The gene discussed is NFKB1; the disease is neoplasm.